Hahn Capital Management LLC Decreases Position in Agilent Technologies, Inc. $A

Key Points

• Hahn Capital Management LLC has reduced its stake in Agilent Technologies by 10.3%, selling 6,849 shares and holding 59,852 shares, which constitute 3.4% of its total assets now valued at approximately $7 million.
• Several hedge funds have increased their positions in Agilent Technologies, with D. E. Shaw & Co. Inc. notably boosting its holdings by 183.7% during the fourth quarter.
• Analysts have set a consensus price target of $139.25 for Agilent Technologies, with ratings varying from “Buy” to “Hold” from various investment firms.

Hahn Capital Management LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 10.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,852 shares of the medical research company's stock after selling 6,849 shares during the period. Agilent Technologies makes up approximately 3.4% of Hahn Capital Management LLC's investment portfolio, making the stock its 16th largest holding. Hahn Capital Management LLC's holdings in Agilent Technologies were worth $7,001,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC lifted its stake in Agilent Technologies by 3.0% in the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company's stock valued at $403,000 after buying an additional 102 shares during the period. Cary Street Partners Financial LLC raised its position in shares of Agilent Technologies by 2.9% during the first quarter. Cary Street Partners Financial LLC now owns 3,688 shares of the medical research company's stock worth $431,000 after purchasing an additional 103 shares during the period. Western Pacific Wealth Management LP raised its position in shares of Agilent Technologies by 15.2% during the first quarter. Western Pacific Wealth Management LP now owns 873 shares of the medical research company's stock worth $102,000 after purchasing an additional 115 shares during the period. Bartlett & CO. Wealth Management LLC raised its position in shares of Agilent Technologies by 5.1% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 2,406 shares of the medical research company's stock worth $281,000 after purchasing an additional 116 shares during the period. Finally, Brighton Jones LLC raised its position in shares of Agilent Technologies by 2.6% during the first quarter. Brighton Jones LLC now owns 4,784 shares of the medical research company's stock worth $560,000 after purchasing an additional 121 shares during the period.

Insiders Place Their Bets

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at $4,397,893.12. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Wall Street Zen lowered Agilent Technologies from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. UBS Group dropped their price target on Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a research report on Thursday, May 29th. TD Cowen raised their price target on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. JPMorgan Chase & Co. decreased their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a report on Thursday, May 29th. Finally, Wells Fargo & Company increased their price objective on Agilent Technologies from $140.00 to $150.00 and gave the stock an "overweight" rating in a report on Monday. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $140.08.

Agilent Technologies Stock Performance

Shares of NYSE A traded up $0.74 during midday trading on Wednesday, hitting $127.93. 563,685 shares of the company's stock were exchanged, compared to its average volume of 1,942,000. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company's 50 day moving average price is $120.01 and its 200 day moving average price is $115.85. The firm has a market capitalization of $36.27 billion, a PE ratio of 30.05, a price-to-earnings-growth ratio of 3.91 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, hitting the consensus estimate of $1.37. The business had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The firm's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.